Guide to COVID-19 Vaccination Schedules



This resource summarizes key information about COVID-19 vaccination schedules. Reference CDC's <u>Clinical Considerations for Use of COVID-19 Vaccines</u> for detailed information and recommendations.

Table 1A: FDA-authorized or approved COVID-19 vaccine options

Vaccine Product	Age Requirement	Vial Cap/Label Colors	Dilution Requirement	Primary Series/Additional Dose	Booster Dose
Pfizer-BioNTech (Fact Sheet)	6 months through 4 years	Maroon	2.2 mL 0.9% NaCl Inj.	0.2 mL (3 mcg)	Not yet
Pfizer-BioNTech (Fact Sheet)	5-11 years	Orange	1.3 mL 0.9% NaCl Inj.	0.2 mL (10 mcg)	0.2 mL (10 mcg)
Pfizer-BioNTech (Fact Sheet)	≥12 years	Purple	1.8 mL 0.9% NaCl Inj.	0.3 mL (30 mcg)	
Pfizer-BioNTech (Fact Sheet)	≥12 years	Gray	Do NOT dilute	0.3 mL (30 mcg)	

continues





Table 1B: FDA-authorized or approved COVID-19 vaccine options continued

Vaccine Product	Age Requirement	Vial Cap/Label Colors	Dilution Requirement	Primary Series/Additional Dose	Booster Dose
Moderna (Fact Sheet)	6 months through 5 years	Blue cap/ magenta label	Do NOT dilute	0.25 mL (25 mcg)	Not yet
Moderna (Fact Sheet) *Product not yet available; use product listed below	6-11 years	Blue cap/ teal label	Do NOT dilute	0.5 mL (50 mcg)	Not yet
Moderna (Fact Sheet)	6-11 years (Primary dose) ≥18 years (Booster dose)	Blue cap/ purple label	Do NOT dilute	6-11 years: 0.5 mL (50 mcg)	≥18 years: 0.5 mL (50 mcg)
Moderna (<u>Fact Sheet)</u>	≥12 years	Red cap/ light blue label	Do NOT dilute	≥12 years: 0.5 mL (100 mcg)	≥18 years: 0.25 mL (50 mcg)
Janssen (J&J) (<u>Fact Sheet)</u>	≥18 years	Light Blue	Do NOT dilute	0.5 mL	0.5 mL



COVID-19 vaccination schedules: key concepts

The following diagrams summarize the current COVID-19 vaccination schedules based on age (diagram 1 and 3) and based on age for people who are moderately or severely immunocompromised (diagram 2 and 4). When using the diagrams below, reference table 1 (above) for the appropriate dose based on the product and the indication (primary, additional, or booster dose). Reference CDC's <u>Clinical Considerations for Use of COVID-19 Vaccines</u> for detailed information and recommendations.

- 1. All time intervals listed in the diagram below indicate the **minimum time interval between doses.**
 - a. Be aware that on a case-by-case basis, CDC guidance allows providers who care for moderately or severely immunocompromised patients (diagram 2 and 4) to administer mRNA COVID-19 vaccines based on clinical judgment, outside FDA and CDC dosing intervals.
- 2. The **Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine** are supplied as different product formulations. The dilution requirements and recommended use differs for each product. It is important to adhere to the recommended product options and use for each age group.
- 3. Pfizer-BioNTech and Moderna COVID-19 vaccines are preferentially recommended in most situations compared to Janssen (J&J) COVID-19 vaccine; the Janssen (J&J) vaccine may be considered in some situations.
- 4. The **same mRNA vaccine product** should be used for all doses of the primary series, whenever possible. Exceptions and guidance for special circumstances, including managing age transitions, is available.
- 5. An 8-week interval in the primary series *may* be preferred as a way to reduce the risk of myocarditis. This is especially true for males ages 12 through 39 years, who are not moderately or severely immunocompromised, and for whom there is not increased concern about community transmission or severe disease.
- 6. Individuals aged ≥18 years may choose which vaccine they receive as a booster dose.

Disclaimer: Information related to the COVID-19 pandemic is changing rapidly and continuously. The material and information contained in this publication is believed to be current as of the date included on this document. The American Pharmacists Association assumes no responsibility for the accuracy, timeliness, errors or omission contained herein. Links to any sources do not constitute any endorsement of, validity, or warranty of the information contained on any site. The user of these materials should not under any circumstances solely rely on, or act based on this publication. Pharmacy professionals retain the responsibility for using their own professional judgment and practicing in accordance with all rules, regulations, and laws governing the pharmacy practice within their jurisdiction.





Diagram 1: Most adolescents and children 6 months through 18 years






Diagram 2: Adolescents and children 6 months through 18 years with moderate to severe immunocompromise






Diagram 3: Most people over 18 years






Diagram 4: Adults over 18 years with moderate to severe immunocompromise

